https://pharminent.com/novartis-drops-als-for-lifonebart-after-astrals-misses-every-endpoint-but-keeps-the-molecule-in-alzheimers/ 2026-09-16T20:11:34Z Pharminent en Novartis Drops ALS for Lifonebart After Astrals Misses Every Endpoint — but Keeps the Molecule in Alzheimer's 2026-09-16T19:51:38Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-september-15-2026/ 2026-09-16T17:50:05Z Pharminent en Oncology Intelligence Digest • September 15, 2026 2026-09-16T17:49:59Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-16-2026/ 2026-09-16T17:43:55Z Pharminent en Strategic News Watch • September 16, 2026 2026-09-16T17:43:51Z Blog https://pharminent.com/gsk-licenses-a-preclinical-trispecific-t-cell-engager-from-chinas-chimagen-for-up-to-750m-in-myeloma/ 2026-09-15T20:21:02Z Pharminent en GSK Licenses a Preclinical Trispecific T Cell Engager From China's Chimagen for Up to $750M in Myeloma 2026-09-15T20:20:41Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-15-2026/ 2026-09-15T20:11:16Z Pharminent en Strategic News Watch • September 15, 2026 2026-09-15T20:11:14Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-september-14-2026/ 2026-09-15T18:39:47Z Pharminent en Rare Disease & Gene Therapy Digest • September 14, 2026 2026-09-15T18:39:44Z Blog